Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Axial Spondyloarthritis - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 23 Nov 17

The "Axial Spondyloarthritis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Axial Spondyloarthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 1 and 1 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Axial Spondyloarthritis - Overview
  3. Axial Spondyloarthritis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Axial Spondyloarthritis - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Axial Spondyloarthritis - Companies Involved in Therapeutics Development
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Novartis AG
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.